FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-028
Estimated average b	ourden
hours per response	٨

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response																
1. Name and Address of Reporting Person * OLUKOTUN ADEOYE Y				2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner							
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVENUE, SUITE 1608			3. Date of Earliest Transaction (Month/Day/Year) 05/04/2020						0	Officer (give title below) Other (specify below)							
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ For	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu						uired, D	ired, Disposed of, or Beneficially Owned							
1.Title of S (Instr. 3)	1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye		ary (Month/Day/Year) Execution Date, if any (Ins		Fransaction de str. 8)	(A (Ir	(A) or Disposed of (Instr. 3, 4 and 5)					() () () () () () () () () ()	ownership orm: oirect (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Reminder:	Report on a s	separate line for each	h class of securities b	eneficia	lly ov	wned dire	ctly		-								
Reminder:	Report on a s	separate line for each		I - Deriv	vative	Securiti	ies A	Pe in a c	ersons this fo curren Dispos	who respon orm are not re tly valid OME ed of, or Bene	equire 3 cont ficially	ed to res trol num	spond ur iber.				1474 (9-02)
	•		Table I	I - Deriv (e.g.,	vative puts,	Securiti	ies A	equired,	ersons this fo curren Dispos ns, con	orm are not re tly valid OME ed of, or Bene vertible secur	equire 3 cont ficially ties)	ed to restrol num	spond ur iber.	nless the f	orm display	S	, ,
1. Title of Derivative	2. Conversion	3. Transaction	Table I 3A. Deemed Execution Date, if	1 - Deriv (e.g.,) 4. Transac Code	vative puts,	Securiti	er ative s l (A) sed	cquired, nts, optio 6. Date Expirati (Month/	Prisons this for current Disposes in contract Co	orm are not retly valid OME ed of, or Bene vertible securiable and	ficially ties) 7. Tof U	ed to res trol num	Amount	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Owners: Form of Derivati Security Direct (i or Indirect)	11. Natur of Indirec Beneficia Ownershi (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table I 3A. Deemed Execution Date, if any	1 - Deriv (e.g.,) 4. Transac Code	vative puts,	e Securiticalls, was 5. Number of Derivas Securities Acquired or Disposof (D) (Instr. 3, and 5)	er ative s l (A) sed	cquired, nts, optio 6. Date Expirati (Month/	Dispos ns, con Exercision Date Day/Ye	orm are not retly valid OME ed of, or Bene vertible securiable and	ficially ties) 7. Tof U	ed to restrol num y Owned Fitle and Underlyin curities str. 3 and	Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Owners Form of Derivati Security Direct () or Indire	11. Natur of Indirec Beneficia Ownershi (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
OLUKOTUN ADEOYE Y C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 1608 NEW YORK, NY 10022	X					

Signatures

/s/ Jessica Morris, Attorney-in-Fact	05/06/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.